Manoguerra Anthony S, Erdman Andrew R, Booze Lisa L, Christianson Gwenn, Wax Paul M, Scharman Elizabeth J, Woolf Alan D, Chyka Peter A, Keyes Daniel C, Olson Kent R, Caravati E Martin, Troutman William G
American Association of Poison Control Centers, Washington, District of Columbia 20016 , USA.
Clin Toxicol (Phila). 2005;43(6):553-70. doi: 10.1081/clt-200068842.
From 1983 to 1991, iron caused over 30% of the deaths from accidental ingestion of drug products by children. An evidence-based expert consensus process was used to create this guideline. Relevant articles were abstracted by a trained physician researcher. The first draft of the guideline was created by the primary author. The entire panel discussed and refined the guideline before its distribution to secondary reviewers for comment. The panel then made changes in response to comments received. The objective of this guideline is to assist poison center personnel in the appropriate out-of-hospital triage and initial management of patients with suspected ingestions of iron by 1) describing the manner in which an ingestion of iron might be managed, 2) identifying the key decision elements in managing cases of iron ingestion, 3) providing clear and practical recommendations that reflect the current state of knowledge, and 4) identifying needs for research. This guideline applies to ingestion of iron alone and is based on an assessment of current scientific and clinical information. The expert consensus panel recognizes that specific patient care decisions may be at variance with this guideline and are the prerogative of the patient and the health professionals providing care, considering all of the circumstances involved. The panel's recommendations follow; the grade of recommendation is in parentheses. 1) Patients with stated or suspected self-harm or who are victims of malicious administration of an iron product should be referred to an acute care medical facility immediately. This activity should be guided by local poison center procedures. In general, this should occur regardless of the amount ingested (Grade D). 2) Pediatric or adult patients with a known ingestion of 40 mg/kg or greater of elemental iron in the form of adult ferrous salt formulations or who have severe or persistent symptoms related to iron ingestion should be referred to a healthcare facility for medical evaluation. Patients who have ingested less than 40 mg/kg of elemental iron and who are having mild symptoms can be observed at home. Mild symptoms such as vomiting and diarrhea occur frequently. These mild symptoms should not necessarily prompt referral to a healthcare facility. Patients with more serious symptoms, such as persistent vomiting and diarrhea, alterations in level of consciousness, hematemesis, and bloody diarrhea require referral. The same dose threshold should be used for pregnant women, however, when calculating the mg/kg dose ingested, the pre-pregnancy weight of the woman should be used (Grade C). 3) Patients with ingestions of children's chewable vitamins plus iron should be observed at home with appropriate follow-up. The presence of diarrhea should not be the sole indicator for referral as these products are often sweetened with sorbitol. Children may need referral for the management of dehydration if vomiting or diarrhea is severe or prolonged (Grade C). 4) Patients with unintentional ingestions of carbonyl iron or polysaccharide-iron complex formulations should be observed at home with appropriate follow-up (Grade C). 5) Ipecac syrup, activated charcoal, cathartics, or oral complexing agents, such as bicarbonate or phosphate solutions, should not be used in the out-of-hospital management of iron ingestions (Grade C). 6) Asymptomatic patients are unlikely to develop symptoms if the interval between ingestion and the call to the poison center is greater than 6 hours. These patients should not need referral or prolonged observation. Depending on the specific circumstances, follow-up calls might be indicated (Grade C).
1983年至1991年期间,铁剂导致儿童意外摄入药品所致死亡的比例超过30%。本指南是通过循证专家共识流程制定的。相关文章由一名经过培训的内科医师研究员进行摘要。指南初稿由第一作者撰写。在将指南分发给二级审阅者征求意见之前,整个专家小组对其进行了讨论和完善。然后,专家小组根据收到的意见进行了修改。本指南的目的是通过以下方式协助中毒控制中心人员对疑似铁剂摄入患者进行适当的院外分诊和初始处理:1)描述铁剂摄入的处理方式;2)确定铁剂摄入病例处理中的关键决策要素;3)提供反映当前知识水平的清晰实用的建议;4)确定研究需求。本指南仅适用于铁剂摄入情况,且基于对当前科学和临床信息的评估。专家共识小组认识到,具体的患者护理决策可能与本指南不一致,在考虑所有相关情况后,这是患者及提供护理的医疗专业人员的特权。专家小组的建议如下;建议等级在括号内。1)有明确或疑似自伤行为或为铁剂恶意投毒受害者的患者应立即转诊至急性护理医疗机构。此行动应遵循当地中毒控制中心的程序。一般来说,无论摄入剂量多少均应如此(D级)。2)已知摄入40mg/kg或更多成人亚铁盐制剂形式的元素铁,或有与铁剂摄入相关的严重或持续症状的儿科或成年患者应转诊至医疗机构进行医学评估。摄入元素铁少于40mg/kg且症状较轻的患者可在家中观察。呕吐和腹泻等轻微症状很常见。这些轻微症状不一定需要转诊至医疗机构。有更严重症状的患者,如持续呕吐和腹泻、意识水平改变、呕血和便血,则需要转诊。孕妇应使用相同的剂量阈值,然而,在计算摄入的mg/kg剂量时,应使用该女性孕前体重(C级)。3)摄入儿童咀嚼型维生素加铁剂的患者应在家中观察并进行适当随访。腹泻不应作为转诊的唯一指标,因为这些产品通常用山梨醇调味。如果呕吐或腹泻严重或持续时间较长,儿童可能需要转诊以处理脱水问题(C级)。4)意外摄入羰基铁或多糖铁复合物制剂的患者应在家中观察并进行适当随访(C级)。5)吐根糖浆、活性炭、泻药或口服络合剂,如碳酸氢盐或磷酸盐溶液,不应在铁剂摄入的院外处理中使用(C级)。6)如果摄入与致电中毒控制中心之间的间隔大于6小时,无症状患者不太可能出现症状。这些患者不需要转诊或长时间观察。根据具体情况,可能需要进行随访电话(C级)。